IP Receptor Antibody (B-6): sc-515139

IP Receptor Antibody (B-6) is a mouse monoclonal IgM antibody that detects IP Receptor of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Anti-IP Receptor antibody (B-6) is available as the non-conjugated form. IP Receptor plays a crucial role in mediating the effects of prostacyclin (PGI2), a key prostanoid synthesized in vascular tissues, which is vital for regulating vascular tone and platelet function. Prostacyclin is known for its ability to inhibit platelet aggregation and induce vasodilation, making prostacyclin an important factor in cardiovascular health. Upon binding to IP Receptor, prostacyclin activates adenylate cyclase through the Gas protein, leading to increased levels of cyclic AMP, which further promotes vasodilation and inhibits platelet activation. The gene encoding human IP Receptor is located on chromosome 19 and is expressed as a glycosylated and phosphorylated protein, predominantly found in vascular tissues such as the aorta, lung, atrium, and ventricle, as well as in the kidney, thymus, spleen, and neurons. Understanding IP Receptor function and prostacyclin interaction is essential for developing therapeutic strategies for conditions like hypertension and other cardiovascular diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

IP Receptor Antibody (B-6) References:

1. Prostanoid receptors: subtypes and signaling.  |  Breyer, RM., et al. 2001. Annu Rev Pharmacol Toxicol. 41: 661-90. PMID: 11264472
2. Protein kinase A-mediated phosphorylation of serine 357 of the mouse prostacyclin receptor regulates its coupling to G(s)-, to G(i)-, and to G(q)-coupled effector signaling.  |  Lawler, OA., et al. 2001. J Biol Chem. 276: 33596-607. PMID: 11443126
3. Central nociceptive role of prostacyclin (IP) receptor induced by peripheral inflammation.  |  Doi, Y., et al. 2002. Neuroreport. 13: 93-6. PMID: 11924902
4. Iloprost. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peripheral vascular disease, myocardial ischaemia and extracorporeal circulation procedures.  |  Grant, SM. and Goa, KL. 1992. Drugs. 43: 889-924. PMID: 1379160
5. Effects of TRA-418, a novel TP-receptor antagonist, and IP-receptor agonist, on human platelet activation and aggregation.  |  Miyamoto, M., et al. 2003. Br J Pharmacol. 140: 889-94. PMID: 14504133
6. Vasoactive mediators derived from the endothelium.  |  Botting, R. and Vane, JR. 1989. Arch Mal Coeur Vaiss. 82 Spec No 4: 11-4. PMID: 2514650
7. Stimulation of fat storage by prostacyclin and selective agonists of prostanoid IP receptor during the maturation phase of cultured adipocytes.  |  Khan, F., et al. 2016. Cytotechnology. 68: 2417-2429. PMID: 26946143
8. Structural organization and chromosomal assignment of the human prostacyclin receptor gene.  |  Ogawa, Y., et al. 1995. Genomics. 27: 142-8. PMID: 7665161
9. Pharmacodynamic profile of prostacyclin.  |  Vane, JR. and Botting, RM. 1995. Am J Cardiol. 75: 3A-10A. PMID: 7840052
10. Molecular cloning of human prostacyclin receptor cDNA and its gene expression in the cardiovascular system.  |  Nakagawa, O., et al. 1994. Circulation. 90: 1643-7. PMID: 7923647
11. In situ hybridization studies of prostacyclin receptor mRNA expression in various mouse organs.  |  Oida, H., et al. 1995. Br J Pharmacol. 116: 2828-37. PMID: 8680713
12. Agonist-dependent phosphorylation of an epitope-tagged human prostacyclin receptor.  |  Smyth, EM., et al. 1996. J Biol Chem. 271: 33698-704. PMID: 8969241

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-IP Receptor Antibody (B-6) has 1 citations in a variety of scientific publications.

Primary antibodies like Anti-IP Receptor Antibody (B-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

IP Receptor Antibody (B-6) Specifications

Alternate Product Name: IP Receptor

Product Clone Name: B-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids: 365-389

Epitope Target: IP Receptor

Epitope Species: mouse

Product Reactivity/Detection: IP Receptor

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 1 citations in various scientific publications

Available Conjugates/Forms for IP Receptor Antibody (B-6): P: Blocking Peptide